المؤلفون: Kanbour, Sarah, Jones, Marissa, Abusamaan, Mohammed, Nass, Caitlin, Everett, Estelle, Wolf, Risa, Sidhaye, Aniket, Mathioudakis, Nestoras

المصدر: Diabetes reviews (Alexandria, Va.). 46(1)

مصطلحات موضوعية: Child, Adolescent, Humans, Adult, Diabetes Mellitus, Type 1, Retrospective Studies, Cohort Studies, Blood Glucose, Academic Medical Centers

الوصف: OBJECTIVE: Recent studies highlight racial disparities in insulin pump (PUMP) and continuous glucose monitor (CGM) use in children and adolescents with type 1 diabetes (T1D). This study explored racial disparities in diabetes technology among adult patients with T1D. RESEARCH DESIGN AND METHODS: This was a retrospective clinic-based cohort study of adult patients with T1D seen consecutively from April 2013 to January 2020. Race was categorized into non-Black (reference group) and Black. The primary outcomes were baseline and prevalent technology use, rates of diabetes technology discussions (CGMdiscn, PUMPdiscn), and prescribing (CGMrx, PUMPrx). Multivariable logistic regression analysis evaluated the association of technology discussions and prescribing with race, adjusting for social determinants of health and diabetes outcomes. RESULTS: Among 1,258 adults with T1D, baseline technology use was significantly lower for Black compared with non-Black patients (7.9% vs. 30.3% for CGM; 18.7% vs. 49.6% for PUMP), as was prevalent use (43.6% vs. 72.1% for CGM; 30.7% vs. 64.2% for PUMP). Black patients had adjusted odds ratios (aORs) of 0.51 (95% CI 0.29, 0.90) for CGMdiscn and 0.61 (95% CI 0.41, 0.93) for CGMrx. Black patients had aORs of 0.74 (95% CI 0.44, 1.25) for PUMPdiscn and 0.40 (95% CI, 0.22, 0.70) for PUMPrx. Neighborhood context, insurance, marital and employment status, and number of clinic visits were also associated with the outcomes. CONCLUSIONS: Significant racial disparities were observed in discussions, prescribing, and use of diabetes technology. Further research is needed to identify the causes behind these disparities and develop and evaluate strategies to reduce them.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/5gv083gfTest

المؤلفون: León-Reyes, Guadalupe, Argoty-Pantoja, Anna D, Rivera-Paredez, Berenice, Hidalgo-Bravo, Alberto, Flores, Yvonne N, Salmerón, Jorge, Velázquez-Cruz, Rafael

المصدر: Nutrients. 15(2)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Public Health, Health Sciences, Clinical Sciences, Nutrition and Dietetics, Cardiovascular, Genetics, Nutrition, Prevention, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Metabolic and endocrine, Humans, Adult, Female, Cohort Studies, Cholesterol, HDL, Diet, Alleles, Nutrients, ATP Binding Cassette Transporter 1, Nucleotide Transport Proteins, hypoalphalipoproteinemia, gene-gene interaction, gene-diet interaction, rs17120425, rs1784042, rs9282541, Mexican population, gene–diet interaction, gene–gene interaction, Food Sciences, Clinical sciences, Nutrition and dietetics, Public health

الوصف: Previous studies have reported that the SIDT2 and ABCA1 genes are involved in lipid metabolism. We aimed to analyze the association-the gene x gene interaction between rs17120425 and rs1784042 on SIDT2 and rs9282541 on ABCA1 and their diet interaction on the HDL-c serum levels-in a cohort of 1982 Mexican adults from the Health Workers Cohort Study. Demographic and clinical data were collected through a structured questionnaire and standardized procedures. Genotyping was performed using a predesigned TaqMan assay. The associations and interactions of interest were estimated using linear and logistic regression. Carriers of the rs17120425-A and rs1784042-A alleles had slightly higher blood HDL-c levels compared to the non-carriers. In contrast, rs9282541-A was associated with low blood HDL-c levels (OR = 1.34, p = 0.013). The rs1784042 x rs9282541 interaction was associated with high blood HDL-c levels (p = 3.4 × 10-4). Premenopausal women who carried at least one rs17120425-A allele and consumed high dietary fat, protein, monounsaturated, or polyunsaturated fatty acids levels had higher HDL-c levels than the non-carriers. These results support the association between the genetic variants on SIDT2 and ABCA1 with HDL-c levels and suggest gene-gene and gene-diet interactions over HDL-c concentrations in Mexican adults. Our findings could be a platform for developing clinical and dietary strategies for improving the health of the Mexican population.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/0b78s714Test

المؤلفون: Columbres, Rod Carlo Agram, Chin, Yue, Pratti, Sanjana, Quinn, Colin, Gonzalez-Cuyar, Luis F, Weiss, Michael, Quintero-Rivera, Fabiola, Kimonis, Virginia

المصدر: Genes. 14(3)

مصطلحات موضوعية: Biological Sciences, Genetics, Rare Diseases, Neurodegenerative, Aging, Brain Disorders, 2.1 Biological and endogenous factors, Aetiology, Neurological, Adult, Humans, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Osteitis Deformans, Valosin Containing Protein, Cell Cycle Proteins, Merozoite Surface Protein 1, Myositis, Inclusion Body, valosin-containing protein, VCP, IBMPFD, ALS, multisystem proteinopathy-1, MSP1

الوصف: Valosin-containing protein (VCP) gene mutations have been associated with a rare autosomal dominant, adult-onset progressive disease known as multisystem proteinopathy 1 (MSP1), or inclusion body myopathy (IBM), Paget's disease of bone (PDB), frontotemporal dementia (FTD), (IBMPFD), and amyotrophic lateral sclerosis (ALS). We report the clinical and genetic analysis findings in five patients, three from the same family, with novel VCP gene variants: NM_007126.5 c.1106T>C (p.I369T), c.478G>A (p.A160T), and c.760A>T (p.I254F), associated with cardinal MSP1 manifestations including myopathy, PDB, and FTD. Our report adds to the spectrum of heterozygous pathogenic variants found in the VCP gene and the high degree of clinical heterogeneity. This case series prompts increased awareness and early consideration of MSP1 in the differential diagnosis of myopathies and/or PDB, dementia, or ALS to improve the diagnosis and early management of clinical symptoms.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/4dj0h013Test

المؤلفون: Perry, Lauren M, Cruz, Sylvia M, Kleber, Kara T, Judge, Sean J, Darrow, Morgan A, Jones, Louis B, Basmaci, Ugur N, Joshi, Nikhil, Settles, Matthew L, Durbin-Johnson, Blythe P, Gingrich, Alicia A, Monjazeb, Arta Monir, Carr-Ascher, Janai, Thorpe, Steve W, Murphy, William J, Eisen, Jonathan A, Canter, Robert J

المصدر: Journal for ImmunoTherapy of Cancer. 11(1)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Human Genome, Vaccine Related, Clinical Research, Genetics, Cancer, Adult, Humans, Virome, Sarcoma, Prognosis, Extremities, Killer Cells, Natural, Soft Tissue Neoplasms, Tumor Microenvironment, sarcoma, immunomodulation, immunotherapy, programmed cell death 1 receptor, tumor biomarkers, Oncology and carcinogenesis

الوصف: BackgroundGroundbreaking studies have linked the gut microbiome with immune homeostasis and antitumor immune responses. Mounting evidence has also demonstrated an intratumoral microbiome, including in soft tissue sarcomas (STS), although detailed characterization of the STS intratumoral microbiome is limited. We sought to characterize the intratumoral microbiome in patients with STS undergoing preoperative radiotherapy and surgery, hypothesizing the presence of a distinct intratumoral microbiome with potentially clinically significant microbial signatures.MethodsWe prospectively obtained tumor and stool samples from adult patients with non-metastatic STS using a strict sterile collection protocol to minimize contamination. Metagenomic classification was used to estimate abundance using genus and species taxonomic levels across all classified organisms, and data were analyzed with respect to clinicopathologic factors.ResultsFifteen patients were enrolled. Most tumors were located at an extremity (67%) and were histologic grade 3 (87%). 40% were well-differentiated/dedifferentiated liposarcoma histology. With a median follow-up of 24 months, 4 (27%) patients developed metastases, and 3 (20%) died. Despite overwhelming human DNA (>99%) intratumorally, we detected a small but consistent proportion of bacterial DNA (0.02-0.03%) in all tumors, including Proteobacteria, Bacteroidetes, and Firmicutes, as well as viral species. In the tumor microenvironment, we observed a strong positive correlation between viral relative abundance and natural killer (NK) infiltration, and higher NK infiltration was associated with superior metastasis-free and overall survival by immunohistochemical, flow cytometry, and multiplex immunofluorescence analyses.ConclusionsWe prospectively demonstrate the presence of a distinct and measurable intratumoral microbiome in patients with STS at multiple time points. Our data suggest that the STS tumor microbiome has prognostic significance with viral relative abundance associated with NK infiltration and oncologic outcome. Additional studies are warranted to further assess the clinical impact of these findings.

الوصول الحر: https://escholarship.org/uc/item/0m8443xqTest

المؤلفون: Besançon, Stéphane, Govender, Denira, Sidibé, Assa Traore, Noble, Janelle Annette, Togo, Amagara, Lane, Julie Ann, Mack, Steven John, Atkinson, Mark A, Wasserfall, Clive Henry, Kakkat, Faizy, Martin, Gregory GN, Ogle, Graham David

المصدر: Pediatric Diabetes. 23(8)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Diabetes, Autoimmune Disease, Pediatric, Clinical Research, Metabolic and endocrine, Adolescent, Adult, Child, Child, Preschool, Female, Humans, Infant, Male, Young Adult, Autoantibodies, C-Peptide, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Genetic Predisposition to Disease, Glutamate Decarboxylase, HLA-DRB1 Chains, Mali, autoantibody, childhood diabetes, C-peptide, HLA, Paediatrics and Reproductive Medicine, Endocrinology & Metabolism, Clinical sciences, Paediatrics

الوصف: ObjectiveLimited information is available regarding youth-onset diabetes in Mali. We investigated demographic, clinical, biochemical, and genetic features in new diabetes cases in children and adolescents.Research design and methodsThe study was conducted at Hôpital du Mali in Bamako. A total of 132 recently-diagnosed cases

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/2843g5wmTest

المؤلفون: Lake, Jordan E, Wang, Ruibin, Barrett, Benjamin W, Bowman, Emily, Hyatt, Ana N, Debroy, Paula, Candelario, Jury, Teplin, Linda, Bodnar, Kaitlin, McKay, Heather, Plankey, Michael, Brown, Todd T, Funderburg, Nicholas, Currier, Judith S

المصدر: AIDS. 36(13)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Prevention, Cardiovascular, HIV/AIDS, Infectious Diseases, Good Health and Well Being, 1-Alkyl-2-acetylglycerophosphocholine Esterase, Adult, Biomarkers, Cardiovascular Diseases, Cohort Studies, Endothelins, Female, HIV Infections, Hormones, Humans, Inflammation, Interleukin-6, Interleukin-8, Lipopolysaccharide Receptors, Lipoproteins, LDL, Male, Middle Aged, P-Selectin, Plasminogen Activator Inhibitor 1, Receptor for Advanced Glycation End Products, von Willebrand Factor, cardiovascular biomarkers, feminizing hormonal therapy, HIV, trans women, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology, Biomedical and clinical sciences, Health sciences

الوصف: BackgroundFeminizing hormonal therapy (FHT) and HIV potentially alter cardiovascular disease (CVD) risk in transgender women (TW).MethodsTW were enrolled in Los Angeles, California and Houston, Texas and frequency-matched to Multicenter AIDS Cohort Study cisgender men (CM) on age, race, substance use, and abacavir use. Biomarkers of CVD risk and inflammation were assessed via ELISA. Wilcoxon rank sum and Fisher's exact tests compared TW and CM. Multivariable linear regression assessed factors associated with biomarker concentrations.ResultsTW (HIV+ n  = 75, HIV- n  = 47) and CM (HIV+ n  = 40, HIV- n  = 40) had mean age 43-45 years; TW/CM were 90%/91% non-Hispanic Black, Hispanic, or Multiracial, 26%/53% obese, and 34%/24% current smokers; 67% of TW were on FHT. Among people with HIV (PWH), TW had higher median extracellular newly-identified receptor for advanced glycation end-products (EN-RAGE), lipoprotein-associated phospholipase A2 (LpPLA2), oxidized low-density lipoprotein (oxLDL), soluble tumor necrosis factor receptor type (sTNFR) I/II, interleukin (IL)-8 and plasminogen activator inhibitor (PAI)-1, but lower soluble CD14, von Willebrand factor (vWF) and endothelin (ET)-1 levels than CM. Findings were similar for participants without HIV (all P

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/7842k8nbTest

المؤلفون: Pettus, Jeremy, Boeder, Schafer C, Christiansen, Mark P, Denham, Douglas S, Bailey, Timothy S, Akturk, Halis K, Klaff, Leslie J, Rosenstock, Julio, Cheng, Mickie HM, Bode, Bruce W, Bautista, Edgar D, Xu, Ren, Yan, Hai, Thai, Dung, Garg, Satish K, Klein, Samuel

المصدر: Nature Medicine. 28(10)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Clinical Sciences, Diabetes, Autoimmune Disease, Prevention, Clinical Trials and Supportive Activities, Clinical Research, 5.1 Pharmaceuticals, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Development of treatments and therapeutic interventions, Metabolic and endocrine, Adult, Antibodies, Monoclonal, Humanized, Blood Glucose, Blood Glucose Self-Monitoring, Diabetes Mellitus, Type 1, Double-Blind Method, Glucagon, Glycated Hemoglobin, Humans, Insulin, Lipoproteins, LDL, Receptors, Glucagon, Transaminases, Treatment Outcome, Medical and Health Sciences, Immunology, Biomedical and clinical sciences, Health sciences

الوصف: Hyperglucagonemia contributes to hyperglycemia in patients with type 1 diabetes (T1D); however, novel therapeutics that block glucagon action could improve glycemic control. This phase 2 study evaluated the safety and efficacy of volagidemab, an antagonistic monoclonal glucagon receptor (GCGR) antibody, as an adjunct to insulin therapy in adults with T1D. The primary endpoint was change in daily insulin use at week 12. Secondary endpoints included changes in hemoglobin A1c (HbA1c) at week 13, in average daily blood glucose concentration and time within target range as assessed by continuous blood glucose monitoring (CGM) and seven-point glucose profile at week 12, incidence of hypoglycemic events, the proportion of subjects who achieve HbA1c reduction of ≥0.4%, volagidemab drug concentrations and incidence of anti-drug antibodies. Eligible participants (n = 79) were randomized to receive weekly subcutaneous injections of placebo, 35 mg volagidemab or 70 mg volagidemab. Volagidemab produced a reduction in total daily insulin use at week 12 (35 mg volagidemab: -7.59 units (U) (95% confidence interval (CI) -11.79, -3.39; P = 0.040 versus placebo); 70 mg volagidemab: -6.64 U (95% CI -10.99, -2.29; P = 0.084 versus placebo); placebo: -1.27 U (95% CI -5.4, 2.9)) without meeting the prespecified significance level (P

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/4zh8n26kTest

المؤلفون: Russell, Steven, Beck, Roy, Damiano, Edward, El-Khatib, Firas, Ruedy, Katrina, Balliro, Courtney, Li, Zoey, Calhoun, Peter, Wadwa, R, Buckingham, Bruce, Zhou, Keren, Daniels, Mark, Raskin, Philip, White, Perrin, Lynch, Jane, Pettus, Jeremy, Hirsch, Irl, Goland, Robin, Buse, John, Kruger, Davida, Mauras, Nelly, Muir, Andrew, McGill, Janet, Cogen, Fran, Weissberg-Benchell, Jill, Sherwood, Jordan, Castellanos, Luz, Hillard, Mallory, Tuffaha, Marwa, Putman, Melissa, Sands, Mollie, Forlenza, Gregory, Slover, Robert, Messer, Laurel, Cobry, Erin, Shah, Viral, Polsky, Sarit, Lal, Rayhan, Ekhlaspour, Laya, Hughes, Michael, Basina, Marina, Hatipoglu, Betul, Olansky, Leann, Bhangoo, Amrit, Forghani, Nikta, Kashmiri, Himala, Sutton, Francoise, Choudhary, Abha, Penn, Jimmy, Jafri, Rabab, Rayas, Maria, Escaname, Elia, Kerr, Catherine, Favela-Prezas, Ruby, Trikudanathan, Subbulaxmi, Williams, Kristen, Leibel, Natasha, Kirkman, M, Bergamo, Kate, Klein, Klara, Dostou, Jean, Machineni, Sriram, Young, Laura, Diner, Jamie, Bhan, Arti, Jones, J, Benson, Matthew, Bird, Keisha, Englert, Kimberly, Permuy, Joe, Cossen, Kristina, Felner, Eric, Salam, Maamoun, Silverstein, Julie, Adamson, Samantha, Cedeno, Andrea, Meighan, Seema, Dauber, Andrew, Boeder, Schafer

المصدر: The New England Journal of Medicine. 387(13)

مصطلحات موضوعية: Adolescent, Adult, Aged, Bionics, Blood Glucose, Blood Glucose Self-Monitoring, Child, Diabetes Mellitus, Type 1, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Insulin Aspart, Insulin Infusion Systems, Insulin Lispro, Middle Aged, Young Adult

الوصف: BACKGROUND: Currently available semiautomated insulin-delivery systems require individualized insulin regimens for the initialization of therapy and meal doses based on carbohydrate counting for routine operation. In contrast, the bionic pancreas is initialized only on the basis of body weight, makes all dose decisions and delivers insulin autonomously, and uses meal announcements without carbohydrate counting. METHODS: In this 13-week, multicenter, randomized trial, we randomly assigned in a 2:1 ratio persons at least 6 years of age with type 1 diabetes either to receive bionic pancreas treatment with insulin aspart or insulin lispro or to receive standard care (defined as any insulin-delivery method with unblinded, real-time continuous glucose monitoring). The primary outcome was the glycated hemoglobin level at 13 weeks. The key secondary outcome was the percentage of time that the glucose level as assessed by continuous glucose monitoring was below 54 mg per deciliter; the prespecified noninferiority limit for this outcome was 1 percentage point. Safety was also assessed. RESULTS: A total of 219 participants 6 to 79 years of age were assigned to the bionic-pancreas group, and 107 to the standard-care group. The glycated hemoglobin level decreased from 7.9% to 7.3% in the bionic-pancreas group and did not change (was at 7.7% at both time points) in the standard-care group (mean adjusted difference at 13 weeks, -0.5 percentage points; 95% confidence interval [CI], -0.6 to -0.3; P

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/1m5021wbTest

المؤلفون: Ogura, Koichi, Elkrief, Arielle, Bowman, Anita S, Koche, Richard P, de Stanchina, Elisa, Benayed, Ryma, Mauguen, Audrey, Mattar, Marissa S, Khodos, Inna, Meyers, Paul A, Healey, John H, Tap, William D, Hameed, Meera, Zehir, Ahmet, Shukla, Neerav, Sawyers, Charles, Bose, Rohit, Slotkin, Emily, Ladanyi, Marc

المصدر: JCO Precision Oncology. 6(6)

مصطلحات موضوعية: Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biotechnology, Pediatric Cancer, Genetics, Human Genome, Pediatric, Clinical Research, Cancer, 2.1 Biological and endogenous factors, Aetiology, Adult, Biological Products, Genomics, Humans, Mutation, Neuroectodermal Tumors, Primitive, Peripheral, Prospective Studies, Receptor, Fibroblast Growth Factor, Type 1, Repressor Proteins, Sarcoma, Ewing, United States, Oncology and carcinogenesis

الوصف: PurposeEwing sarcoma (ES) is a primitive sarcoma defined by EWSR1-ETS fusions as the primary driver alteration. To better define the landscape of cooperating secondary genetic alterations in ES, we analyzed clinical genomic profiling data of 113 patients with ES, a cohort including more adult patients (> 18 years) and more patients with advanced stage at presentation than previous genomic cohorts.MethodsThe data set consisted of patients with ES prospectively tested with the US Food and Drug Administration-cleared Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets large panel, hybrid capture-based next-generation sequencing assay. To assess the functional significance of ERF loss, we generated ES cell lines with increased expression of ERF and lines with knockdown of ERF. We assessed cell viability, clonogenic growth, and motility in these ES lines and performed transcriptomic and epigenetic analyses. Finally, we validated our findings in vivo using cell line xenografts.ResultsNovel subsets were defined by recurrent secondary alterations in ERF, which encodes an ETS domain transcriptional repressor, in 7% of patients (five truncating mutations, one deep deletion, and two missense mutations) and in FGFR1 in another 2.7% (one amplification and two known activating mutations). ERF alterations were nonoverlapping with STAG2 alterations. In vitro, increased expression of ERF decreased tumor cell growth, colony formation, and motility in two ES cell lines, whereas ERF loss induced cellular proliferation and clonogenic growth. Transcriptomic analysis of cell lines with ERF loss revealed an increased expression of genes and pathways associated with aggressive tumor biology, and epigenetic, chromatin-based studies revealed that ERF competes with EWSR1-FLI1 at ETS-binding sites.ConclusionOur findings open avenues to new insights into ES pathobiology and to novel therapeutic approaches in a subset of patients with ES.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/76p9d7skTest

المؤلفون: Xinrui Tan, Xiongfeng Pan, Xiaochuan Wu, Songjia Zheng, Yuyao Chen, Donghai Liu, Xingxing Zhang

المصدر: Frontiers in Pharmacology; 2024, p01-10, 10p

مصطلحات موضوعية: GLUCAGON-like peptide-1 receptor, GLUCAGON-like peptide-1 agonists, TYPE 1 diabetes, INSULIN, INSULIN therapy, DIASTOLIC blood pressure, PEPTIDE receptors

مستخلص: Background: To assess the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) used as an adjunct to insulin therapy in adults with type 1 diabetes. Methods: A search of electronic databases (Medline, Embase, and the Cochrane Central Register of Controlled Trials) from 1 January 1950 to 23 May 2021 was conducted to find randomized controlled trials. The primary outcome was the change in HbA1c. Eight efficacy and six safety secondary endpoints were evaluated via meta-analysis. Weighted mean difference (WMD) and odds ratio (OR), alongside 95% confidence interval (CI), were calculated using the random effects model. Results: Among 1,379 candidate studies, 11 trials comprising 2,856 participants satisfied the inclusion criteria. Overall, GLP-1 RA adjunctive therapy reduced HbA1c by -0.21% (95% CI, -0.33 to -0.10), weight by -4.04 kg (-4.8 to -3.27), systolic pressure by -2.57 mmHg (-4.11 to -1.03), and diastolic blood pressure by -1.02 mmHg (-1.99 to -0.06). In addition, there was a decrease in prandial insulin dose (WMD, -4.23 IU; 95% CI, -5.26 to -3.20), basal insulin dose (-2.40 IU; -3.93 to -0.87), and total insulin dose (-5.73 IU; -10.61 to -0.86). Moreover, GLP-1 RAs did not increase the incidence of severe hypoglycemia, diabetic ketoacidosis, or severe adverse events. However, GLP-1 RAs increased the incidence of gastrointestinal adverse events (OR, 2.96; 95% CI, 2.33-3.77). Conclusion: Our meta-analysis of randomized clinical trials suggests moderate beneficial effects of GLP-1 RAs on the metabolic profile in patients with type 1 diabetes, without an increased risk of serious adverse events. Clinical Trial Registration: https://www.crd.york.ac.uk/PROSPEROTest; Identifier: CRD 42020199840. [ABSTRACT FROM AUTHOR]

: Copyright of Frontiers in Pharmacology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)